• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    M

    Molecular Medicine Ireland

    EST. 2002
    46论文总数
    1,014引用总数

    论文量&引用量时间轴

    机构学者

    论文(46)

    年份
    起
    –
    止
    排序
    1Development and Clinical Validation of a Novel Biopsy-Based Six-Gene Signature to Accurately Risk-Stratify Men with Early-Stage Prostate Cancer to Aid Treatment Decision Making.
    Agnieszka Krzyzanowska,Stephen Barron,Debra Higgins,Tony Loughman,Katherine Sheehan,Angel Chan-Ju Wang,Bozena Fender,Leah M. McGuire,David Jonathan Galvin,Amanda O'Neill,Joanna Fay,Anthony O'Grady,

    374 Background: Prostate cancer (PCa) is diagnosed in over 1.2 million men worldwide annually, making it the second-most common non-cutaneous cancer in men. Most men have indolent PCa and can safely defer treatment with active surveillance. However, many patients are commonly treated with surgery (radical prostatectomy, RP) or radiation therapy, which are associated with a significant reduction in quality of life. Molecular signatures have been developed to assist clinicians in stratifying patients based on their risk of aggressive PCa; while these have shown promise, there remains a significant opportunity for improving prognostic capacity. Methods: A panel of fourteen prognostic genes was identified from The Cancer Genome Atlas Prostate Adenocarcinoma (TCGA PRAD) database. Gene expression was measured by reverse-transcription quantitative polymerase chain reaction in RP samples from an Irish cohort of men diagnosed with PCa and treated with RP (PCRC, n=426). Cross-validated logistic regression analysis identified a six-gene molecular risk score (MRS) with strong prognostic performance to predict aggressive PCa, i.e., adverse pathology (AP) at RP or biochemical recurrence (BCR). The MRS was combined with the Cancer of the Prostate Risk Assessment (CAPRA) score to create a molecular plus clinical risk score (MCRS). The MRS and MCRS were clinically validated in biopsy samples from an independent Swedish cohort of men diagnosed with PCa and treated by RP (UPCA, n=100). Results: We identified a six-gene signature, consisting of four prognostic and two reference genes, with improved prognostic value over clinical features. In the clinical biopsy validation study univariable analysis, the AUC of the signature for AP was 0.72 (MRS) and 0.82 (MCRS) versus 0.72 for EAU risk categories and 0.82 for CAPRA. The C-index for BCR was 0.62 (MRS) and 0.74 (MCRS) versus 0.65 for EAU risk categories and 0.73 for CAPRA. Furthermore, in bivariable analysis, the six-gene signature added statistically significant (p < 0.001) prognostic value to EAU risk categories and CAPRA. Conclusions: The six-gene prognostic signature has strong performance for AP and BCR in an independent clinical biopsy validation study. MCRS can provide improved prognostic stratification and inform optimal patient management post-diagnosis.

    2023JOURNAL OF CLINICAL ONCOLOGY(2023)
    引用
    AI阅读
    加入学术空间
    2Optimising Outcomes in Chronic Heart Failure
    Ify Mordi,Benjamin R. Szwejkowski
    2020Practitioner(2020)引用:23
    引用
    AI阅读
    加入学术空间
    3PATIENT-REPORTED OUTCOME MEASURES AND USER EXPERIENCE FOLLOWING SIX MONTHS' ENROLMENT IN A DIABETES DIGITAL HEALTH SERVICE: MYDIABETESMYWAY: INFORMATICS IN THE SERVICE OF MEDICINE; TELEMEDICINE, SOFTWARE AND OTHER TECHNOLOGIES
    Christopher Shields,Rachel Nutt,Deborah J. Wake,Doogie Brodie,Scott Cunningham,Tim Benson,Alex Bickerton, N. Conway
    2020
    引用
    AI阅读
    加入学术空间
    4Primary and Secondary Vasospastic Disorders (raynaud’s Phenomenon) and Vasculitis
    Andrew Melville, J. J. F. Belch
    2019
    引用
    AI阅读
    加入学术空间
    5Metformin and Its Potential for Heart Failure with Preserved Ejection Fraction
    Mohapradeep Mohan,Zaid Iskandar,Ify Mordi,Casserene Yeow, Alex Neaogoie,Graham Rena, Samuel Teong Huang Chew,Chim C. Lang

    The health burden of Heart Failure with Preserved Ejection Fraction (HFpEF) is substantial. In some countries, HFpEF is the leading cause of hospital admission in patients over 65 years of age and is predicted to be the leading cause of mortality within a decade [1,2]. HFpEF is characterised by reduced exercise capacity and ability to engage in activities of daily living, poor HealthRelated Quality of Life (HRQoL), high rates of hospitalisation, and premature mortality [3]. In sharp contrast to the wealth of proven therapies for Heart Failure with Reduced Ejection Fraction (HFrEF) that have improved mortality and morbidity, there is a distinct lack of treatment options for HFpEF. Drugs or devices which are recommended in current HF treatment guidelines to improve outcomes in HFrEF have not been shown to have similar benefit in HFpEF patients, and to date, phase III randomised controlled trials have not consistently yielded evidence-based therapy for HFpEF [4]. The lack of treatment options in patients with HFpEF represents a significant unmet need that urgently demand new therapeutic strategies that arguably target mechanisms specific for HFpEF.

    2019Journal of Diabetes and Treatment(2019)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 46 篇论文

    合作机构(88)

    圣文森特大学医院合作论文 6
    三一学院都柏林合作论文 6
    圣詹姆斯医院合作论文 6
    Mercy University Hospital合作论文 5
    Mater Misericordiae University Hospital合作论文 4
    都柏林大学学院合作论文 4
    博蒙特医院合作论文 4
    St Vincent''s Hospital,St Vincent''s Health合作论文 4
    塔拉特大学医院合作论文 3
    皇家爱尔兰外科医学院合作论文 3

    机构统计